Dallas 2015 TFQO: Jan Jensen COI #115 EVREVs: Jan Jensen COI #115 Richard N. Bradley COI #151 Taskforce: First Aid 769: Hemostatic Dressings.

Slides:



Advertisements
Similar presentations
Dallas 2015 TFQO: Tony Scott #138 EVREV 1: Tony Scott #138 EVREV 2: Anthony Seto # Taskforce: ACS Supplemental Oxygen in ACS 887.
Advertisements

Dallas 2015 TFQO: Allan de Caen COI#38 EVREV 1: Melissa Parker COI#259 EVREV 1: Takanari Ikeyama COI#235 Taskforce: Pediatrics Peds 820 : The use of fluids.
Dallas 2015 TFQO: Myra Wyckoff #COI EVREV 1: Myra Wyckoff #COI EVREV 2: Lindsay Mildenhall #107 Taskforce: NRP NRP: 605 Two thumb verses two finger.
Dallas 2015 TFQO: Marya Strand, MD, MS; COI#222 EVREV 1: Marya Strand, MD, MS; COI#222 EVREV 1: Takahiro Sugiura, MD; COI#224 Taskforce: NLS Umbilical.
Dallas : CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room,
Chicago 2014 TFQO: Kee-Chong Ng (#COI = 113) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: S. Velaphi COI #242 EVREVs: N. Singhal COI#213 H. Ersdal COI#76 Taskforce: Neonatal Maintaining Infant Temperature During Delivery Room.
Dallas 2015 TFQO: EVREVs: de Almeida, Maria Fernanda COI# Trevisanuto, Daniele COI# Taskforce: Neonatal Warming Adjunts #599 Among preterm neonates who.
Chicago 2014 Peter Morley, Eddy Lang E3, GRADE expert Incorporating lower levels of evidence.
Dallas 2015 TFQO: David Stanton COI 328 EVREVs: Volker Wenzel COI 253& Emmanuelle Bourdon COI 333 Taskforce: BLS Passive ventilation techniques.
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI 261 EVREV 2: Daniel Pichel COI # 513 Taskforce: ACS ACS 335: Pre-hospital ADP- Receptor.
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Charles Deakin COI #221 Taskforce: ALS ALS 714 : Advanced airway placement (SGA.
Peds-818: Pediatric Early Warning Scores
Dallas 2015 TFQO: Vinay Nadkarni MD COI#249 EVREV 1: Graeme Maclaren MBBS COI#98 EVREV 2: Ravi Thiagarajan MBBS, MPH COI#149 Taskforce: PALS Peds 819 :
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI #261 EVREV 2: Daniel Pichel COI #513 Taskforce: ACS ACS 873: Pre-hospital STEMI Activation.
Dallas 2015 TFQO: Jeffry Pearlman COI# 187 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP.
Felix I. Zemel, MPH DrPH Student Tufts University School of Medicine.
Dallas 2015 TFQO: EVREVs: Aaron Donoghue / Jonathan Duff Taskforce: EIT Teaching Compression-Only CPR.
Dallas 2015 TFQO: Masanori Tamura #147 EVREV 1: Masanori Tamura #147 EVREV 2: Susan Niermeyer #252 Delayed Cord Clamping in Preterm Infants Including those.
Lecture 8 Objective 20. Describe the elements of design of observational studies: case reports/series.
NRP: 862: Use of Feedback CPR Devices for Neonatal Cardiac Arrest NRP: 863: Use of Feedback CPR Devices to detect ROSC for Neonatal Cardiac Arrest TFQO:
Chicago 2014 TFQO: Peter Meaney #COI 149 EVREV 1: Richard Aickin #COI 153 EVREV 1: Peter Meaney #COI 149 Taskforce: Pediatrics Resuscitation fluids (Peds)
Dallas 2015 TFQO: Marilyn Escobedo COI#78 EVREV 1: Marilyn Escobedo COI#78 EVREV 2: Henry Lee COI#135 Taskforce: NRP Babies born to mothers who are hypothermic.
Dallas 2015 TFQO: Robert Greif EVREVs: Jan Breckwoldt, Henrik Fischer Taskforce: Education Implementation and Training (EIT) AED training methods.
Evidence Based Medicine Meta-analysis and systematic reviews Ross Lawrenson.
Dallas 2015 TFQO: Enrique Udaeta COI# 239 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP 618)
Systematic Review Module 7: Rating the Quality of Individual Studies Meera Viswanathan, PhD RTI-UNC EPC.
Dallas 2015 TFQO: EVREVs: Guinsburg, Ruth COI# McGowan, Jane COI# Taskforce: Neonatal Apgar Zero #896 In infants ≥36 weeks GA with an Apgar score.
Dallas 2015 TFQO: Name EVREV 1: Jonathan Wyllie COI #282 EVREV 1: Jeff Perlman COI #262 Taskforce: Newborn Temperature Maintenance in the Delivery room.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
Chicago 2014 TFQO: Nikolaos Nikolaou COI#253 EVREV 1: Nikolaos Nikolaou COI#253 EVREV 2: Farzin BeyguiCOI#202 Taskforce: ACS STEMI transfer PCI vs. FL.
Chicago 2014 TFQO: Darren Walters COI #317 EVREV 1: Darren Walters COI #317 EVREV 2: Chris Ghaemmaghami COI #60 Taskforce: Acute Coronary Syndrome In STEMI.
Dallas 2015 TFQO: Anne-Marie Guerguerian # 97 EVREV1: Anne-Marie Guerguerian # 97 EVEREV2: Ericka Fink # 83 Taskforce: PEDS Peds 407 : ECMO for pediatric.
Landmark Trials: Recommendations for Interpretation and Presentation Julianna Burzynski, PharmD, BCOP, BCPS Heme/Onc Clinical Pharmacy Specialist 11/29/07.
Dallas 2015 TFQO: Darren Walters EVREVs: EVREV 1: Darren Walters COI #422 EVREV 2: Chris Ghaemmaghami COI #89 Taskforce: Acute Coronary Syndrome Fibrinolytic.
First Aid 801: Stroke Recognition
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 4 (maximum) using standard.
Dallas 2015 TFQO: David Boyle COI #26 EVREV 1: David Boyle #COI#26 EVREV 1: Jane McGowan #370 Taskforce: Neonatal Ventilation Strategies in the DR (NRP.
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 6 (maximum) using standard.
Dallas 2015 TFQO: Michael Sayre COI #400 EVREV 1: Mohamud Daya COI #327 EVREV 2: Jan-Thorsten Gräsner COI #230 Taskforce: BLS BLS 363: CPR Prior to Defibrillation.
Chicago 2014 TFQO: Charles Deakin #329 EVREV 1: Asger Granfeldt COI #63 EVREV 2: Bo Lofgren COI #363 Taskforce: ALS ALS 571 : Ventilation strategy post-ROSC.
Dallas 2015 TFQO: Allan de Caen COI #38 EVREV 1: Tia Raymond COI #153; EVREV 2: Jonathan Egan COI #44 Taskforce: Peds The role of invasive vascular monitoring.
UT Southwestern Medical Center at Dallas
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
Dallas 2015 TFQO: Kee-Chong Ng (#COI = 170) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: Vinay Nadkarni #375 EVREV 1: Vinay Nadkarni #375 EVREV 1: Dave Kloeck #126 Taskforce: Paeds Paed 424: Vasopressors in Paediatric cardiac.
Chicago 2014 Pediatric RRT/MET Teams #397 TFQO: Dianne Atkins COI #7 EVREV 1: Dianne Atkins EVREV 2: Kee Chong Ng COI #113 Taskforce: Peds.
TFQO: Jasmeet Soar #COI 272 EVREV 1: Jasmeet Soar #COI 272 EVREV 2: Michael Donnino #COI 222 Taskforce: ALS ALS 448 OXYGEN DOSE AFTER ROSC IN ADULTS 3.
Dallas 2015 TFQO: Maaret Castrén #320 EVREV 1: Christian Vaillancourt #416 EVREV 2: Michael Sayre #400 Taskforce: BLS BLS 359: Dispatcher Instructions.
Dallas 2015 TFQO: Monica Kleinman COI #353 EVREV 1: Janice Tijssen COI#232 EVREV 2: Javier Urbano COI#240 Taskforce: Peds Peds 815: Pediatric goal-directed.
Dallas 2015 TFQO: Judith Finn EVREVs: Judith Finn #227 / Dion Stub #COI Taskforce: EIT Cardiac Arrest Centres.
Dallas 2015 TFQO: Michael W. Donnino COI# EVREVs: Katherine M. Berg COI# Lars W. Andersen COI# Taskforce: ALS Ultrasound During CPR.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREV: Michael Reilly COI #193 Taskforce: First Aid First Aid 768: Use of Tourniquet.
Dallas 2015 TFQO: Koen Monsieurs 372 EVREV 1: Koen Monsieurs 372 EVREV 2: Ahamed Idris 349 Taskforce: BLS BLS366 Chest Compression Depth (adults)
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Jan-Thorsten Graesner COI #150 Taskforce: ALS ALS 783 : Advanced versus basic.
Dallas 2015 TFQO: Robert Greif EVREVs: Dana Edelson, COI #334 Robert Greif, COI #344 Taskforce: EIT EIT 645: Debriefing of resuscitation performance.
Dallas 2015 TFQO: Hiroshi Nonogi #254 EVREVs: Hiroshi Nonogi #254 Tony Scott #138 Taskforce: ACS Fibrinolytic and immediate PCI for STEMI 882.
Levels of Evidence Dr Chetan Khatri Steering Committee, STARSurg.
Dallas 2015 TFQO: S. Velaphi EVREV 1: N. Singhal COI #213 EVREV 2: S. Velaphi COI #242 EVREV 3: H. Ersdal – COI # 76 Taskforce: NLS Prognosis: In newborn.
Dallas 2015 TFQO: Karen Woolfrey #COI 261 EVREV 1: Karen Woolfrey # COI 261 EVREV 2: Daniel Pichel #COI 513 Taskforce: ACS ACS 872: Pre-hospital Diversion.
Dallas 2015 TFQO: Name EVREVs: Names and #COI Taskforce: Name Insert Short PICO title Total of 12 (no studies) to 20 slides (maximum) using standard format.
Dallas 2015 TFQO: Jonathan Witt (COI #418) EVREVs: Steve Lin (COI #137), Thomas Pellis (COI #186) and Katie Dainty (COI #) Taskforce: ALS ALS 428 : Antiarrhythmic.
Chicago 2014 TFQO: Clifton Callaway # EVREV 1: Janice Zimmerman # EVREV 2: Jonathan Sullivan COI # Taskforce: ALS ALS 790 : Induced Hypothermia.
Abstract Cardiopulmonary Resuscitation with Rescue Breathing Is Superior to Hands-Only Cardiopulmonary Resuscitation for Children and Infants: Results.
Dallas 2015 TFQO: Jasmeet Soar #COI 409 EVREV 1: Jasmeet Soar #COI 409 EVREV 2: Anthony Lagina #COI 357 Taskforce: ALS ALS 889 OXYGEN DOSE DURING CPR IN.
Dallas 2015 TFQO: Michael Donnino #222 EVREV 1: Joshua Reynolds COI #265 EVREV 2: Katherine Berg COI #10 Taskforce: ALS ALS 790 : Induced Hypothermia.
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Systematic review of Present clinical reality
Why this talk? you will be seeing a lot of GRADE
pulmonary embolism protocol -- EMB review
Presentation transcript:

Dallas 2015 TFQO: Jan Jensen COI #115 EVREVs: Jan Jensen COI #115 Richard N. Bradley COI #151 Taskforce: First Aid 769: Hemostatic Dressings

Dallas 2015 COI Disclosure (specific to this systematic review) Commercial/industry Jensen – None Bradley – None Potential intellectual conflicts Jensen – None Bradley Resuscitation Sub-council Chairman, American Red Cross Scientific Advisory Council Board member, Citizen CPR Foundation

Dallas CoSTR Consensus on Science Evidence from 4 LOE 4 studies in adults showed a significant improvement compared with standard treatment for out-of-hospital control of life-threatening bleeding when topical hemostatic agents were used by trained individuals. This beneficial outcome was supported by 21 LOE 5 animal studies. Effectiveness varied substantially among the agents used. Adverse effects of some agents included tissue destruction with induction of a proembolic state and potential thermal injury. Treatment Recommendation The out-of-hospital application of a topical hemostatic agent to control life-threatening bleeding not controlled by standard techniques is reasonable, but the best agent and the conditions under which it should be applied are not known.

Dallas 2015 C2015 PICO Population: patients with severe external bleeding Intervention: the application of topical hemostatic dressings plus standard first aid Comparison: standard first aid alone Outcomes: overall mortality, vital signs, hemostasis, complications, blood loss, major bleeding, incidence of cardiac arrest

Dallas 2015 Inclusion/Exclusion & Articles Found Inclusion criteria: Humans or animals Hemostatic dressings (not granules) External bleeding Exclusion criteria: Not primary research Bleeding not external Bleeding not severe Hemostatic dressing not used or used in combination with other things 1,250 Number of Articles Finally Evaluated

Dallas Proposed Treatment Recommendations We suggest (weak) hemostatic dressings* be used when standard first aid hemorrhage control cannot control bleeding by first aid providers; very low quality of evidence. Values and preferences statement: In making this recommendation, we place increased value on the benefits of hemostasis, which outweigh the risks. The cost of the intervention is moderate. *This PICO specifically addressed hemostatic dressings and does not apply to other agents (such as granules) that may be applied alone or followed by a plain dressing.

Dallas 2015 Risk of Bias: RCT Studies (all animal) StudyYearDesign Total nPopulation Industry Funding Allocation: Generation Allocation: Concealment Blinding: Participants Blinding: Assessors Outcome: Complete Outcome: Selective Other Bias Acheson2005 RCT (animal)45 swine - femoral artery hemorrhageUNCLEAR unclea rhigh low Alam2003 RCT (animal)60 swine - extremity hemorrhageNO unclea r high lowhighunclear Arnaud2009 (632) RCT (animal)16 swine - groin hemorrhageYEShigh low Arnaud2009 (848) RCT (animal)16 swine - groin hemorrhageYEShigh lowhighlow Causey2012 RCT (animal)17 swine - femoral artery hemorrhageUNCLEARhigh lowhighlow Devlin2011 RCT (animal)24 swine - groin hemorrhageYEShigh lowhighlow Kheirabadi2009 RCT (animal)16 swine - femoral artery hemorrhageYEShigh lowhighlow Kozen2008 RCT (animal)24 swine - groin hemorrhageYEShigh lowhighlow

Dallas 2015 Risk of Bias: non-RCT Studies (human) StudyYearDesign Total PatientsPopulation Industry Funding Eligibility Criteria Exposure/ Outcome Confounding Follow-Up Brown2009 retrospective case series34 EMS patients - severe external bleedingunclearhigh low Cox2009 retrospective case series18 Military - severe external bleedingnohigh Ran2010 retrospective case series14 Military - severe external bleedingunclearhigh low Wedmore2006 retrospective case series64 Military - severe external bleedingnohigh low

Dallas 2015 Evidence profile table(s)

Dallas 2015 Evidence profile table(s)

Dallas 2015 Evidence profile table(s)

Dallas 2015 Proposed Consensus on Science statements For the critical outcome of “overall mortality”, we have identified very low quality evidence from one human case series showing benefit, where 21% (1/26) of patients receiving hemostatic dressings died. We also identified very low quality evidence from seven animal studies showing benefit, where 40.7% (25/86) of patients who received hemostatic dressings died, compared to 65.8% (54/82) who did not receive hemostatic dressings (RR 0.62 (0.46 – 0.83)).

Dallas 2015 Proposed Consensus on Science statements For the critical outcome of “hemostasis”, very low quality evidence from four human case series enrolling 130 participants showing benefit where hemostasis occurred in 90.8% of participants (no comparison group). We also identified very low quality evidence from three animal studies showing benefit where hemostasis occurred in 74.2% (23/31), compared to 50% (13/26) (RR 1.48 (0.96 – 2.30)).

Dallas 2015 Proposed Consensus on Science statements For the critical outcome of “complications”, very low quality evidence from four human case series studies enrolling 96 participants showing benefit that complications from hemostatic dressing occur in 3% (3/96) of participants (no comparison group). For the important outcome of “time to bleeding cessation”, very low quality evidence from one human case series showing benefit that 73% (25/34) of participants achieved hemostasis in under three minutes with a hemostatic dressing applied (no comparison group).

Dallas 2015 Draft Treatment Recommendations We suggest (weak) hemostatic dressings* be used when standard first aid hemorrhage control cannot control bleeding by first aid providers; very low quality of evidence. Values and preferences statement: In making this recommendation, we place increased value on the benefits of hemostasis, which outweigh the risks. The cost of the intervention is moderate. *This PICO specifically addressed hemostatic dressings and does not apply to other agents (such as granules) that may be applied alone or followed by a plain dressing.

Dallas 2015 Knowledge Gaps How much training is required and what type of training should be used for first aid providers to apply hemostatic dressings to bleeding wounds Which specific hemostatic dressings should be used by first aid providers? In humans, how do hemostatic dressings compare to properly applied standard first aid providers?

Dallas 2015 Next Steps Consideration of interim statement Person responsible Due date